1 Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial The Lancet Oncology, May 16, 2013
2 Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care, May 8, 2013
3 Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-l) Diabetes Care, May 1, 2013
4 Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial Diabetes Care, May 10, 2013
5 Thickness of superficial basal cell carcinoma predicts imiquimod efficacy, a proposal for thickness-based definition of superficial basal cell carcinoma British Journal of Dermatology, May 2, 2013
6 Hair Cortisol as a Biomarker of Traumatization in Healthy Individuals and Posttraumatic Stress Disorder Patients Biological Psychiatry, April 29, 2013
7 Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study BMC Gastroenterology, May 15, 2013
8 Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors Clinical Cancer Research, May 2, 2013
9 Fast Evaluation of 69 Basal Cell Carcinomas With Ex Vivo Fluorescence Confocal Microscopy Criteria Description, Histopathological Correlation, and Interobserver Agreement Fast Evaluation of 69 Basal Cell Carcinomas JAMA Dermatology, May 3, 2013
10 Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring Expert Review of Anticancer Therapy, May 16, 2013
Sponsor
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor